Navigation Links
Cancer Experts Meet in Boston to Discuss a Promising Approach to Treating the Disease

CAMBRIDGE, Mass., Oct. 21, 2013 /PRNewswire/ -- Academics, healthcare providers, and pharmaceutical industry professionals are gathered in Boston to discuss the latest advances in cancer research. The evening of Tuesday, October 22, those professionals are invited to attend a symposium that will explore one of the most exciting targets in cancer treatment, a protein called hypoxia-inducible factor-1a, or HIF-1a.

The role of HIF-1a in solid tumors has been well documented. It is often present in solid tumors where hypoxic, or low oxygen, conditions are common, and its presence may be increased by anti-angiogenic medicines and radiation. Because HIF-1a can promote resistance, leaders in government, academia, and industry have long sought an effective HIF-1a inhibitor. This week, experts will discuss whether the potential of HIF-1a inhibition is soon to become a reality.

The pre-clinical panel features Giovanni Melillo, MD, of AstraZeneca and formerly of the National Cancer Institute; Sarah Conley, PhD, of MedImmune and formerly of the Max Wicha Lab at the University of Michigan; Amato Giaccia, PhD, of Stanford University; and Robert Kerbel, PhD, of the University of Toronto.

The clinical panel features William Kaelin, MD, of Harvard Medical School; Laura Benjamin, PhD, of Eli Lilly; Mark Dewhirst, DVM, PhD, of Duke University School of Medicine; and Steve Keefe, MD, of the Abramson Cancer Center at the University of Pennsylvania.

Oliver Fetzer, PhD, President and CEO of symposium sponsor, Cerulean Pharma, will welcome attendees, and Robert A. Weinberg, PhD, of the Massachusetts Institute of Technology, will provide closing remarks. WHO: Academics, professionals, and journalists interested in the latest research on the HIF-1a protein and the advances that illustrate its value as a target for new medicinesWHAT: HIF-1a: Ready for Prime Time? includes pre-clinical and clinical panels, closing remarks, a poster exhibition, and a dinner receptionWHEN: Tuesday, October 22, 2013, from 5:30 p.m. to 9:30 p.m.WHERE: Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115REGISTER: Online at, via email at with "HIF Symposium" in the subject line, or by phone at 845-265-2155 specifying "HIF Symposium"; please note institution, degree, and phone number when registering; there is no fee 

Media Contact: 
Laura Kempke or Kristin Villiotte 
Schwartz MSL 
+1 781-684-0770

SOURCE Cerulean Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
2. Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
3. Nucletron, an Elekta Company, Receives U.S. FDA 510(k) Clearance for Esteya Electronic Brachytherapy System for Treating Skin Cancer
4. IceCure Enters a New High-Potential Market: The company received $100K-order for cryoablation consoles and probes to be used in a clinical study for the treatment of lung cancer
5. Sedationless Colonoscopy Option May Increase Colorectal Cancer Screening Compliance
6. Hologic to Mark Start of Breast Cancer Awareness Month with NASDAQ Opening Bell Ceremony
7. First urine-based cancer mutation monitoring test available from Trovagene
8. Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the American Association for the Study of Liver Diseases
9. Varians Calypso Tumor Tracking System Used in Lung, Stomach and Prostate Cancer Treatments at Leading European Cancer Center
10. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
11. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
Post Your Comments:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):